newsfilter
← Latest News
GlobeNewswire·

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

– Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to robust long-term clinical responses and was well tolerated; Phase 3 ONWARD